InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,539.10
(
0.55%
)
US TECH 100
19,737.60
(
0.49%
)
Dow Jones
39,197.54
(
-0.28%
)
Brent Oil
86.99
(
-0.40%
)
Bitcoin
55,494.42
(
-2.61%
)
Post# of 252489
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Titan V

Send PM Follow Ignore
Followers 31
Posts 3757
Boards Moderated 0
Alias Born 01/29/2012

Titan V

Re: None

Thursday, 11/09/2017 6:52:49 AM

Thursday, November 09, 2017 6:52:49 AM

Post# of 252489
SAGE (+68%/PM) Announces Brexanolone Achieves Primary Endpoints in Both Phase 3 Clinical Trials in Postpartum Depression

- Statistically significant mean reduction in the HAM-D score compared to placebo at 60 hours demonstrated in both trials

- Brexanolone provided a rapid and durable reduction over 30 days in depressive symptoms as measured by HAM-D in both placebo-controlled multi-center trials

- Positive results support planned regulatory submissions; Company to host conference call today at 8:00 A.M. ET

http://www.businesswire.com/news/home/20171109005296/en/Sage-Therapeutics-Announces-Brexanolone-Achieves-Primary-Endpoints
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up